--- title: "Weekly Recap | LABU.US +2.63%, XBI names hit 52-week highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/298106371.md" description: "LABU closed the week at $303.55, up 2.63% from $295.76 the previous Friday, while the S&P 500 added just 0.09%, leaving the ETF about 2.54 percentage points ahead. The path was uneven: Monday opened lower and touched $281.50 before a rebound took hold. Wednesday spiked to $327.02 intraday, but Thursday and Friday pulled back, and the fund settled above $303." datetime: "2026-09-05T09:08:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298106371.md) - [en](https://longbridge.com/en/news/298106371.md) - [zh-HK](https://longbridge.com/zh-HK/news/298106371.md) generator: "portal-rs" --- # Weekly Recap | LABU.US +2.63%, XBI names hit 52-week highs ## The Week LABU closed the week at $303.55, up 2.63% from $295.76 the previous Friday, while the S&P 500 added just 0.09%, leaving the ETF about 2.54 percentage points ahead. The path was uneven: Monday opened lower and touched $281.50 before a rebound took hold. Wednesday spiked to $327.02 intraday, but Thursday and Friday pulled back, and the fund settled above $303. ## SPDR S&P Biotech This Week The underlying SPDR S&P Biotech (XBI) rose 0.88% to $163.81, from $162.38 the prior week. The swing was narrower than LABU’s, with a high near $168.06 and a low near $159.62, amplitude 5.24%. The shape matched: XBI hit its weekly high on Wednesday and drifted lower over the final two sessions. ## Leverage & Decay LABU tracks 3x the daily move of XBI, not 3x the weekly cumulative return. With XBI up 0.88% this week, the theoretical 3x gain was about 2.64%; LABU delivered 2.63%, a gap of just -0.01%. That gap comes from daily rebalancing. In a week with a fairly continuous upward drift, decay is minimal. In choppy, range-bound conditions, the daily reset would drag long-term returns more visibly. This week’s pattern, three up days followed by two down days, sat close enough to a straight path that the drag was negligible. ## SPDR S&P Biotech News Several XBI constituents hit 52-week highs this week, including Halozyme, Travere and Inhibikase. Moderna finished 5.48% higher after Merck trial headlines, though the stock wobbled intraweek; Natera added 0.59% and traded near record levels; Revolution Medicines rose 1.03% after RASONQUE data landed. In contrast, Twist Bioscience fell 11.78%, giving back the prior week’s gain. The tone was one of sector-wide warmth with sharp single-name divergence. ## The Week Ahead Thursday carries the bulk of US macro data: jobless claims, final-demand PPI, existing home sales and wholesale sales. Initial claims come in at a prior 206 with consensus 205; core final-demand PPI was 4.2 and is expected at 4.6. After Friday’s jobs report, the debate about the Fed’s September rate path remains live, making inflation readings the near-term focus. For LABU, the question is whether XBI can hold the 163-164 area and whether the names that made new highs see profit-taking. ## In Short LABU’s 2.63% weekly gain tracked XBI’s 0.88% move cleanly, with negligible decay, suggesting the underlying trend was steady enough. But the intraweek spike to $327 and the sharp sell-off in Twist Bioscience show the tape was not uniform. On the latest session, retail-size flow tilted toward net selling, while large-lot flow was flat on both sides; PE and PB for this leveraged product are not meaningful for valuation context. The next test is whether inflation and claims data keep the rate-sensitive biotech growth trade intact, and whether XBI extends its run or consolidates after the new highs. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Baird Financial Group Inc. Sells 187,448 Shares of DuPont de Nemours, Inc. $DD](https://longbridge.com/en/news/298823649.md) - [Comcast Details Split Plan as Broadband, Wireless Competition Intensifies](https://longbridge.com/en/news/298775015.md) - [Squarepoint Ops LLC Purchases 268,939 Shares of Lsb Industries Inc. $LXU](https://longbridge.com/en/news/298825051.md) - [NEOS Investment Management LLC Buys 38,043 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/298824702.md) - [Burford Brothers Inc. Decreases Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298797379.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**